- SG$38.45m
- -SG$19.45m
- SG$27.84m
- 11
- 45
- 64
- 32
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.32 | ||
| Price to Tang. Book | 0.43 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.38 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -10.92% | ||
| Return on Equity | -14.73% | ||
| Operating Margin | -73.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SG$m | 50.62 | 56.67 | 55.16 | 55.73 | 27.84 | n/a | n/a | -14.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -32.91 | +46.19 | -30.4 | -20.83 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cordlife Group Limited is a Singapore-based company that owns cord blood banks in Asia, mainly in Hong Kong, Indonesia, Philippines, India, and Malaysia. The Company’s segments include Banking and Diagnostics. The banking segment comprises the collection, processing, and banking of biological materials. The diagnostics segment comprises diagnostics testing services. Its banking services include cord blood, cord lining, cord lining mesenchymal stem cells, corneal lenticule, cord lining epithelial stem cells, cord tissue, and others. Its diagnostic testing services include newborn genetic screening, pediatric vision screening, pediatric ear screening, pediatric allergen test, genetic talent test, preimplantation genetic screening, endometrial receptivity test, non-invasive prenatal testing, lifestyle genetic screening, and newborn metabolic screening. Its Moms Up is a mobile app offering pregnancy, as well as parenting resources for moms and moms-to-be in Asia.
Directors
- Choon Hou Ho CHM (43)
- Poh Lan Tan CEO (57)
- Choo Boon Yong CFO (48)
- Hnin Yi Thet FID
- Siew Koon Ang SEC
- Bing Chuen Chen NED (39)
- Xiaoling Chen NED (30)
- Wai Leong Chow NED (53)
- Ming Yiu Yiu NED (33)
- Lingyun Zhai NED (47)
- Yan Titus Jim Cheong IND (58)
- Hwee Tiong Yeo IND (61)
- Wai Leung Wong NID (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 2nd, 2001
- Public Since
- March 29th, 2012
- No. of Employees
- 111
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Singapore Exchange Securities Trading Ltd- Shares in Issue
- 256,307,744
- Address
- 1 Yishun Industrial Street 1, 768160
- Web
- http://www.cordlife.com/sg/en/
- Phone
- +65 62380808
- Contact
- Kamal Samuel
- Auditors
- KPMG Phoomchai Audit Ltd.
Upcoming Events for P8A
Similar to P8A
Alliance Healthcare
Singapore Exchange Securities Trading Ltd
Aoxin Q & M Dental
Singapore Exchange Securities Trading Ltd
Asiamedic
Singapore Exchange Securities Trading Ltd
Asia Vets Holdings
Singapore Exchange Securities Trading Ltd
Beverly JCG
Singapore Exchange Securities Trading Ltd
FAQ
What is the Cordlife share price?
As of Today at 20:04 UTC, shares in Cordlife are trading at SG$0.15. This share price information is delayed by 15 minutes.
How has the Cordlife share price performed this year?
Shares in Cordlife last closed at SG$0.15 and the price had moved by +21.95% over the past 365 days. In terms of relative price strength the Cordlife share price has outperformed the FTSE Developed Asia Pacific Index by +25.42% over the past year.
What are the analyst and broker recommendations for Cordlife?
There is no consensus recommendation for this security.
Find out moreWhat is the Cordlife dividend yield?
Cordlife does not currently pay a dividend.
Does Cordlife pay a dividend?
Cordlife does not currently pay a dividend.
When does Cordlife next pay dividends?
Cordlife does not currently pay a dividend.
How do I buy Cordlife shares?
To buy shares in Cordlife you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cordlife?
As of the previous close price of SG$0.15, shares in Cordlife had a market capitalisation of SG$38.45m.
Where are Cordlife shares listed?
Here are the trading details for Cordlife:
- Country of listing: Singapore
- Exchange: SES
- Ticker Symbol: P8A
What kind of share is Cordlife?
Based on an overall assessment of its quality, value and momentum Cordlife is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cordlife share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Cordlife share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cordlife. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -0.81%.
As of the last closing price of SG$0.15, shares in Cordlife were trading -10.23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cordlife PE Ratio?
The Cordlife PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SG$0.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cordlife?
Cordlife's management team is headed by:
- Choon Hou Ho - CHM
- Poh Lan Tan - CEO
- Choo Boon Yong - CFO
- Hnin Yi Thet - FID
- Siew Koon Ang - SEC
- Bing Chuen Chen - NED
- Xiaoling Chen - NED
- Wai Leong Chow - NED
- Ming Yiu Yiu - NED
- Lingyun Zhai - NED
- Yan Titus Jim Cheong - IND
- Hwee Tiong Yeo - IND
- Wai Leung Wong - NID